Ozempic Prescribed: Eligibility, Results, and Safety Considerations

Ozempic (semaglutide) has become one of the most talked-about medications in the UK, and interest in Ozempic Glasgow continues to grow as more patients seek clinically supervised treatment. . But with all the headlines, it can be difficult to separate the facts from the noise. Here is what the clinical evidence, and current NICE guidance, actually tells us about who qualifies, what results to expect, and what every patient should know before starting treatment.

Understanding Semaglutide: How It Works

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists (glucagon-like peptide-1). It works by mimicking a naturally occurring hormone that your body releases after eating, which plays several important roles simultaneously.

In the brain, it acts on areas that regulate appetite, reducing hunger signals and making you feel full for longer after meals. In the pancreas, it stimulates insulin secretion in response to elevated blood glucose, while also suppressing glucagon, the hormone that raises blood sugar. It also slows gastric emptying, meaning food moves through your stomach more slowly, which further supports feelings of satiety.

The result is a drug that works on multiple pathways at once: glycaemic control, appetite regulation, and ultimately weight management.

Who Is Eligible? The NICE Criteria Explained

NICE Technology Appraisal TA875 (published March 2023, updated September 2023) sets out clear criteria for when semaglutide (Wegovy) can be recommended within specialist NHS weight management services in England.

Core eligibility requirements

BMI THRESHOLD

≥ 35 kg/m²

Plus at least one weight-related health condition

LOWER BMI ROUTE

30–34.9

If the patient meets NICE criteria for referral to a specialist weight management service

MAXIMUM DURATION

2 Years

Within a specialist multidisciplinary service (Tier 3 or 4)

ETHNIC BACKGROUND

−2.5 kg/m²

Lower thresholds for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds

 

Required weight-related comorbidities

To qualify under NICE criteria, a patient must have at least one of the following alongside the relevant BMI threshold: type 2 diabetes or prediabetes (dysglycaemia), hypertension, dyslipidaemia (high cholesterol or triglycerides), obstructive sleep apnoea, or established cardiovascular disease.

The treatment-response rule

NICE guidance also states that clinicians should consider stopping semaglutide if a patient has not achieved at least 5% of their initial body weight loss after six months at the maintenance dose. This is an important clinical checkpoint designed to ensure the treatment is actually working for that individual.

What about Ozempic for type 2 diabetes?

For patients with type 2 diabetes, Ozempic is prescribed based on individual glycaemic management needs and cardiovascular risk profile. Current NICE diabetes guidelines support the use of GLP-1 receptor agonists, including semaglutide, in patients with type 2 diabetes where there is a high cardiovascular risk or where weight management is a clinical priority. This is assessed on a case-by-case basis by your prescribing doctor.

What the Clinical Evidence Actually Shows

Semaglutide is one of the most extensively studied anti-obesity medications in history. Here is a summary of the key trial data.

The STEP Programme (Weight Management)

The STEP (Semaglutide Treatment Effect in People with obesity) trials were a series of large randomised controlled trials that formed the evidence base for NICE’s approval. The pivotal STEP 1 trial demonstrated that participants taking semaglutide 2.4 mg lost, on average, around 15% of their body weight over 68 weeks, compared to around 2.4% in the placebo group, a difference of approximately 12 percentage points.

~15%

Average body weight reduction in STEP 1 (vs placebo)

20%

Reduction in major cardiovascular events in SELECT

17,604

Patients enrolled in the SELECT trial

4 Years

Weight loss sustained in the SELECT analysis

 

The SELECT Trial (Cardiovascular Outcomes)

The SELECT trial was a landmark cardiovascular outcomes study enrolling 17,604 adults with pre-existing cardiovascular disease, overweight or obesity, and no diabetes. Semaglutide 2.4 mg produced a 20% reduction in major adverse cardiovascular events (MACE), the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke, compared to placebo.

A subsequent long-term analysis of SELECT data, published in Nature Medicine, found that weight loss with semaglutide continued over 65 weeks and was sustained for up to four years, with a mean weight reduction of 10.2% at four years versus 1.5% for placebo. Crucially, the cardiovascular benefit appeared consistent across all BMI categories and both sexes.

Ozempic in type 2 diabetes (SUSTAIN trials)

For patients with type 2 diabetes, the SUSTAIN trial programme demonstrated that semaglutide significantly reduced HbA1c compared with placebo and active comparators, while also producing meaningful weight reduction. The SUSTAIN 6 cardiovascular outcomes trial confirmed a significant reduction in cardiovascular events in patients with type 2 diabetes and high CV risk, establishing the cardioprotective credentials that now inform prescribing decisions.

Safety Considerations: What Every Patient Should Know

Like all prescription medications, semaglutide carries potential side effects and important safety considerations. Proper medical assessment before, and monitoring during, treatment is non-negotiable.

Common side effects

  • Gastrointestinal symptoms Nausea, vomiting, diarrhoea, and constipation are the most frequently reported side effects, particularly during the dose-escalation phase. These are usually temporary and can be managed by starting at the lowest dose and increasing gradually as prescribed.
  • Reduced appetite and fatigue Appetite suppression is the intended therapeutic effect, but some patients experience it as uncomfortable, particularly in the early weeks. Maintaining adequate nutrition and hydration is important.
  • Injection site reactions Redness, swelling, or mild discomfort at the injection site can occur. Rotating the injection site each week minimises this risk.

Serious safety considerations

  • Acute pancreatitis Cases of acute pancreatitis, including serious haemorrhagic and necrotising forms, have been reported. Treatment should be discontinued immediately if pancreatitis is suspected, and should not be restarted if confirmed. Patients with a prior history of pancreatitis require careful evaluation before initiation.
  • Thyroid C-cell tumour risk Animal studies showed dose-dependent thyroid C-cell tumours with semaglutide. Whether this translates to humans is not yet established, but caution is essential. Patients should report any unexplained neck lump, hoarseness, difficulty swallowing, or shortness of breath to their doctor promptly.
  • Acute gallbladder disease Gallstones and acute cholecystitis have been observed in clinical trials. Patients with symptoms of gallbladder disease, such as severe upper-right abdominal pain, should seek medical review.
  • Hypoglycaemia (low blood sugar) Risk is low when semaglutide is used alone, but increases significantly when used alongside a sulfonylurea or insulin. Blood glucose monitoring and dose adjustment of concomitant medications may be required.
  • Gastroparesis Semaglutide delays gastric emptying, which can rarely progress to significant gastric motility issues. It is not recommended in patients with pre-existing severe gastroparesis.

When Ozempic / Semaglutide Must NOT Be Used

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Prior serious hypersensitivity reaction to semaglutide or any excipients
  • Type 1 diabetes mellitus (Ozempic is not indicated for this condition)
  • Pregnancy or planned pregnancy (effective contraception should be used; stop treatment at least 2 months before attempting conception)
  • Concurrent use with another GLP-1 receptor agonist or another semaglutide-containing product

The Importance of Supervised Prescribing

One of the most important clinical considerations around Ozempic and Wegovy is the growing number of patients sourcing these medications through unregulated online channels, often without a proper face-to-face assessment, baseline blood tests, or ongoing clinical support.

NICE guidance specifically states that semaglutide for weight management should be used within a specialist weight management service that provides multidisciplinary care. This is not bureaucratic box-ticking, it exists to protect patients. A thorough consultation should include a review of your full medical history and current medications, baseline measurements and relevant blood work, clear discussion of realistic expectations and lifestyle changes required, and a plan for regular monitoring throughout treatment.

It is also worth noting that Ozempic is currently licensed in the UK only for the management of type 2 diabetes, and Wegovy (the 2.4 mg weight-management formulation) is a distinct, separately licensed product. The two are not interchangeable, and NICE TA875 recommends Wegovy specifically, not Ozempic, for weight management. Patients starting treatment privately should also be aware that NHS GPs are not obligated to continue private semaglutide prescriptions, and those wishing to transition to NHS provision must meet the NICE criteria and be referred to a specialist service.

Lifestyle: The Non-Negotiable Part

The clinical trials that demonstrated semaglutide’s efficacy all involved participants following a reduced-calorie diet and increased physical activity alongside the medication. Semaglutide is not a standalone solution, it is a powerful tool that works best when supported by meaningful lifestyle changes.

Patients who maintain dietary improvements and regular exercise during treatment tend to achieve better outcomes and are better placed to preserve weight loss if the medication is eventually stopped. When semaglutide is discontinued, appetite typically returns to its pre-treatment levels, and weight regain is a documented risk without the foundations of sustainable habits already in place.

The Bottom Line

Semaglutide, whether as Ozempic for type 2 diabetes or Wegovy for weight management, is backed by robust clinical evidence and represents a genuine advance in how we manage metabolic disease. The STEP trials and SELECT cardiovascular outcomes data make a compelling case for its benefits in the right patients.

But “the right patients” is the key phrase. Eligibility criteria, safety screening, and ongoing clinical supervision exist for very good reasons. This is not a medication to obtain and self-administer without proper medical oversight. If you think you might benefit from semaglutide, the right first step is a thorough consultation with a qualified clinician who can assess your full medical picture.

Thinking About Semaglutide?

At Doc Plus, our GP-led weight management clinic provides face-to-face assessments, full medical screening, and ongoing clinical support, everything NICE guidelines require for safe prescribing. Book a consultation today.

Contact us

Get in touch to find out more

    I am interested in:

    Address

    421 Mearns Rd
    Mearnskirk
    Newton Mearns
    Glasgow G77 5RY

    Contact

    Call: 0141 530 5300
    Email: enquiries@docplus.co.uk

    Regulated by Healthcare Improvement Scotland

    Privacy Preference Center

    Find a service

    Health checksBasic · Intermediate · Comprehensive · Tailored
    Ultrasound & pregnancy scansAbdomen · Pelvis · Breast · Pregnancy
    Skin, lumps & hairCysts · Warts · Skin tags · Hair loss
    Joint pain & injectionsSteroid · Ostenil · PRP · Arthrosamid
    Women’s health & contraceptionCoils · Implants · Smears · Well woman
    Men’s health & testosteroneWell man · TRT · Hair loss
    Sexual healthSTI testing · Consultations
    Ears & hearingWax removal · Hearing tests · Hearing aids
    Allergies & hay feverAllergy testing · Hay fever care
    Iron & infusion therapyIron infusions · IV therapy
    Weight managementClinic overview · Treatment information
    GP care & wellbeingSleep · Alcohol · Smoking · Migraines
    Travel & vaccinationsTravel clinic · Family vaccines
    Workplace medicalsOEUK / offshore · Work medicals
    Cosmetic consultationsWrinkles · Lip & dermal fillers